Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corp develops orthobiologic products for spine fusion markets, with its work centered on bone regeneration using the recombinant human protein rhNELL-1. Its lead product candidate, NB1, combines rhNELL-1 with demineralized bone matrix and is tied to the company’s focus on targeted bone regeneration in spinal fusion, with rights also noted for trauma and osteoporosis applications.
News about BBLG commonly covers clinical-development progress, product-readiness milestones such as rhNELL-1 shelf-life validation, patent activity, financing transactions, Nasdaq listing compliance, and corporate updates on scientific and operational priorities.
Bone Biologics Corporation (NASDAQ: BBLG) has announced that its CEO, Jeffrey Frelick, will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A pre-recorded presentation will be available starting January 10 at 7:00 a.m. ET. Interested viewers can access the presentation via the company's investor relations website.
The company specializes in developing orthobiologic products aimed at spinal fusion, focusing on bone regeneration through its innovative research on the Nell-1 protein.
Bone Biologics Corp. (NASDAQ: BBLG) has successfully closed a public offering of 1,510,455 units at $5.25 each, raising approximately $7.9 million. Each unit includes one share of common stock and a warrant, which is exercisable at $6.30 per share for five years. The offering followed a 1-for-2.5 reverse stock split and began trading on Nasdaq on October 13, 2021. The underwriters have a 45-day option to purchase additional securities. This offering is registered under Form S-1 with the SEC, indicating the company’s ongoing efforts in regenerative medicine for bone.
WallachBeth Capital announced the successful completion of an underwritten public offering for Bone Biologics (NASDAQ: BBLG), raising $7.9 million through the sale of 1,510,455 units at an offering price of $5.25 per unit. Each unit includes one share of common stock and one warrant, exercisable at $6.30 per share. The company also granted underwriters a 45-day option to purchase additional shares to cover over-allotments. Following a reverse stock split on October 12, 2021, BBLG and its warrants began trading on Nasdaq on October 13, 2021.
WallachBeth Capital LLC has priced an underwritten public offering of 1,510,455 units of Bone Biologics (NASDAQ: BBLG) at $5.25 per unit, totaling gross proceeds of $7.9 million before expenses. Each unit consists of one share of common stock and one warrant, exercisable at $6.30 for five years. The offering includes a 45-day option for underwriters to purchase additional shares and warrants. A reverse stock split at a 1-for-2.5 ratio was also implemented. Trading for BBLG and BBLGW began on October 13, 2021, with the offering closing expected around October 15, 2021.
Bone Biologics Corp. (NASDAQ: BBLG) announced the pricing of its public offering of 1,510,455 units at $5.25 each, raising gross proceeds of approximately $7.9 million. Each unit comprises one share of common stock and one warrant to buy a share at $6.30, expiring in five years. The offering, effective October 15, 2021, follows a 1-for-2.5 reverse stock split executed on October 12, 2021. Underwriters may purchase an additional 226,568 shares for overallotments. Trading began on October 13, 2021. WallachBeth Capital is the book-running manager.